Affymetrix and Luminex Announce Distribution Agreement for Multiplexed Assay Instrument Platform
October 15 2015 - 6:30AM
Business Wire
Affymetrix Inc. (NASDAQ: AFFX) and Luminex Corporation (NASDAQ:
LMNX) today announced a distribution agreement under which
eBioscience, a business unit of Affymetrix, will sell Luminex’s
MAGPIX®, Luminex® 200™ and FLEXMAP 3D® multiplexed assay platforms
in specified countries in the Americas, Asia and Europe. Affymetrix
will sell the Luminex instruments together with ProcartaPlex®
multiplexed immunoassays and QuantiGene® Plex multiplexed
quantitative gene expression assays, offering complete solutions to
customers working in the fields of drug discovery and development,
immuno-oncology and translational research. The agreement will
strengthen continued growth and adoption of Affymetrix’ bead-based
assay portfolio, which serves markets growing at double-digit rates
worldwide, while expanding the Luminex instrument installed
base.
The distribution agreement covers the U.S., Canada, Mexico,
Brazil and China as well as The Netherlands, Germany, France, U.K.,
Switzerland, Austria, Belgium, Ireland, Luxembourg and Poland.
“We are pleased to enter into this agreement with Luminex, the
leading instrument provider supporting bead-based multiplexed
assays,” said Dara Grantham Wright, senior vice president and
general manager of the eBioscience business unit at Affymetrix.
“This agreement deepens our relationship with Luminex, and will
provide our customers an integrated solution to access a
best-in-class platform with an ever-expanding, high-quality assay
menu.”
“By enabling Affymetrix to offer both Luminex multiplexing
instruments and Affymetrix assays, we can further drive
accessibility to customers focused on disease-related research
around the world,” said Todd Bennett, vice president, global sales
and customer operations, Luminex Corporation. “We are very pleased
to enter into this agreement, and to support Affymetrix in its
efforts to bring flexible, high-quality solutions to laboratories
working in the fields of drug discovery and development,
immuno-oncology and translational research.”
Financial terms were not disclosed.
About xMAP-based Instruments
Luminex offers three multiplex instruments enabling laboratories
to choose a platform that fits their throughput and flexibility
needs. MAGPIX is the simplest, most affordable, and most compact of
Luminex’s xMAP instruments. This compact multiplexing unit performs
up to 50 different tests in a single reaction volume and reads a
96-well plate in just 60 minutes. The Luminex 200 System provides
laboratorians the ability to perform up to 100 different tests in a
single reaction volume while using either magnetic or polystyrene
microspheres. FLEXMAP 3D is the platform of choice for high
throughput applications. The platform is capable of simultaneously
measuring up to 500 genes or proteins from a small sample. All
three xMAP-based instruments run multiplexed assays for proteins or
nucleic acids, whether kit-based or lab-developed.
Learn more about Luminex instruments:
www.luminexcorp.com/instruments
About Luminex Corporation
Luminex is committed to applying its passion for innovation
toward creating breakthrough solutions to improve health and
advance science. The company is transforming global healthcare and
life-science research through the development, manufacturing and
marketing of proprietary instruments and assays utilizing xMAP®
open-architecture multi-analyte platform, MultiCode® real-time
polymerase chain reaction (PCR) and multiplex PCR-based
technologies that deliver cost-effective rapid results to
clinicians and researchers. Luminex's technology is commercially
available worldwide and in use in leading clinical laboratories as
well as major pharmaceutical, diagnostic, biotechnology and
life-science companies. Luminex is meeting the needs of customers
in markets as diverse as clinical diagnostics, pharmaceutical drug
discovery, biomedical research including genomic and proteomic
research, personalized medicine, biodefense research and food
safety. For further information on Luminex Corporation and the
latest advances in multiplexing using award-winning technology,
please visit www.luminexcorp.com.
About Affymetrix
Affymetrix technologies enable multiplex and simultaneous
analysis of biological systems at the cell, protein and gene level,
facilitating the rapid translation of benchtop research into
clinical and routine use for human health and wellness. Affymetrix
provides leadership and support, partnering with customers in
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and nonprofit research institutes in
their quest to use biology for a better world. More than 2,300
microarray systems have been shipped around the world and more than
94,000 peer-reviewed papers have been published citing Affymetrix
technologies. Affymetrix is headquartered in Santa Clara,
California, and has manufacturing facilities in Cleveland, San
Diego, Vienna and Singapore. Affymetrix has about 1,100 employees
and maintains sales and distribution operations worldwide. For more
information about Affymetrix, please visit www.affymetrix.com.
Forward-looking statements
All statements in this press release that are not historical are
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act as amended, including statements
regarding Affymetrix' "expectations," "beliefs," "hopes,"
"intentions," "strategies," or the like. Such statements are
subject to risks and uncertainties that could cause actual results
to differ materially for Affymetrix from those projected. These and
other risk factors are discussed in Affymetrix' Form 10-K for the
year ended December 31, 2014, and other SEC reports for subsequent
quarterly periods.
PLEASE NOTE: Affymetrix, the Affymetrix logo,
eBioscience, ProcartaPlex, and QuantiGenePlex trademarks are the
property of Affymetrix, Inc. All other trademarks are the
property of their respective owners.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151015005456/en/
AffymetrixMedia
Contact:Mindy Lee-Olsen, 408-731-5523Vice President, Marketing
Servicesmindy_lee-olsen@affymetrix.comorInvestor
Contact:Doug Farrell, 408-731-5285Vice President, Investor
Relationsdoug_farrell@affymetrix.comorLuminexMedia Contact:Christine
Valle, 512-219-8020Sr. Manager, Global
Marketingcvalle@luminexcorp.comorLuminex Investor
Contact:Harriss Currie, 512-219-8020Sr. Vice President of
Finance and CFOhcurrie@luminexcorp.com
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Jul 2023 to Jul 2024